Certara, Inc.

CERT

$8.01

-1.54%

2026-09-04 11:48:50 EDT-$0.13

Healthcare

Medical - Healthcare Information Services

NASDAQ

Negociación activa

Certara, Inc. provides advanced software solutions and technology-driven services, specializing in biosimulation throughout the entire drug development lifecycle. From initial drug discovery ...

Evolución del precio de CERT

$8.01

-1.54%-$0.13

Máximo—

Mínimo—

Máx. 52s-42.3%

Vol. rel.—

Intervalo

Rango57m

Volumen—SMA5SMA10

—

Certara, Inc. is a global biosimulation company founded in 2008 and headquartered in Radnor, Pennsylvania. It provides advanced software and technology-driven services to optimize drug development across the entire lifecycle, from discovery and preclinical research to clinical trials, regulatory submissions, and market access. The company's core mission is to accelerate ...Certara, Inc. is a global biosimulation company founded in 2008 and headquartered in Radnor, Pennsylvania. It provides advanced software and technology-driven services to optimize drug development across the entire lifecycle, from discovery and preclinical research to clinical trials, regulatory submissions, and market access. The company's core mission is to accelerate the delivery of new medicines to patients by transforming traditional processes with biosimulation software and expertise. Its portfolio includes mechanistic and empirical biosimulation, strategic guidance for drug development and regulatory affairs, clinical pharmacology, model-based meta-analysis, regulatory writing and communications, and market access consultation. Certara's software platforms cover PK/PD biosimulation, data standardization, regulatory submission authoring, and market access communication. The company serves biopharmaceutical firms, academic institutions, and government organizations. With over 1,515 employees and operations in more than 30 countries, Certara maintains a significant global presence. Key financial metrics indicate a market cap of approximately $1.28 billion, with a focus on revenue generation despite recent net losses. The founding CEO was Jon Resnick, who has been leading the company toward innovation in model-informed drug development. Certara is publicly traded on NASDAQ under the symbol CERT and continues to expand its technological capabilities, as evidenced by initiatives like Certara.AI, which applies artificial intelligence to drug discovery and regulatory processes.ExpandirContraer

Fundación

2008

Empleados

1546

CEO

Jon Resnick

Nombre completo

Certara, Inc.

Sector

Healthcare

Industria

Medical - Healthcare Information Services

ROE

-6.66%

Capitalización

$1.25B

Ratio corriente

2.55

WACC

12.11%

ROIC

2.76%

Información de contacto

https://www.certara.com

609 716 7900

4 Radnor Corporate Center, Radnor, PA 19087

Métricas clave de CERT

Instantánea

Último / TTM · 6 periodos

Capitalización

$1.25B

ROCE

0.6%

EV / EBITDA

16.13x

-0.9% YoY

Rendimiento FCF

5.0%

+0.0% YoY

Ciclo de conversión de efectivo

95.9d

Ratio corriente

2.55

Resumen rápido

TTM —

Positive CCC

Aspectos financieros de CERT

Tendencia de rentabilidad

Último / TTM · 6 periodos

Margen bruto

58.3%

Margen neto

-16.7%

PER

-17.92x

n/d

Deuda / capital

0.30

n/d

Ratio corriente

2.55

Rendimiento del dividendo

0.0%

Comprensión

TTM —

Estos ratios principales no muestran una presión relevante en el balance.

Calendario de CERT

Próximamente

30 sept 2026En 26 días
Q3 FY2026 · Resultados estimados
BPA est. $0.09 · Ingresos $92.75M · 6 analistas
30 dic 2026
Q4 FY2026 · Resultados estimados
BPA est. $0.09 · Ingresos $94.54M · 6 analistas
31 dic 2026
FY2026 · Resultados anuales estimados
BPA est. $0.34 · Ingresos $380.10M · 6 analistas
30 mar 2027
Q1 FY2027 · Resultados estimados
BPA est. $0.11 · Ingresos $96.70M · 2 analistas

Historial reciente

4 ago 2026
Q2 FY2026 · Resultados publicados
BPA $-0.36 · Ingresos $93.27M
Ver documento
11 may 2026
Q1 FY2026 · Resultados publicados
BPA $-0.06 · Ingresos $106.92M
Ver documento
26 feb 2026
FY2025 · Resultados anuales
BPA $-0.01 · Ingresos $418.84M
Ver documento
6 nov 2025
Q3 FY2025 · Resultados publicados
BPA $0.01 · Ingresos $104.62M
Ver documento
6 ago 2025
Q2 FY2025 · Resultados publicados
BPA $-0.01 · Ingresos $104.57M
Ver documento
5 may 2025
Q1 FY2025 · Resultados publicados
BPA $0.03 · Ingresos $106.00M
Ver documento

Estados financieros de CERT

Tendencia de 5 años (ingresos, beneficios, FCF)

Métrica	Último	InteranualYoY significa Year-over-Year (interanual). Compara el último valor anual con el valor anual anterior para mostrar la fortaleza de la tendencia a largo plazo.	TrimestralQoQ significa Quarter-over-Quarter (intertrimestral). Compara el último trimestre con el trimestre inmediatamente anterior para mostrar cambios de impulso a corto plazo.
IngresosEl dinero total que entró por la puerta principal al vender cosas, antes de pagar una sola factura. Piensa en esto como el gran total de cada compra con tarjeta de los clientes. (YoY compara el rendimiento de este año con el del año pasado, mientras que QoQ compara los tres meses actuales con los tres anteriores).	$418.8M	+8.7%	-12.8%
Beneficio netoEl resultado final absoluto. Si la empresa pagara a cada proveedor, empleado, banquero y recaudador de impuestos, este es el dinero real que queda en su bolsillo al final del día.	$-1.6M	+86.8%	-530.7%
Margen brutoEl margen básico. Si venden unas zapatillas de 100 dólares, este porcentaje indica cuánto de ese precio es ganancia justo después de pagar el caucho y los cordones, pero antes de pagar el alquiler de la tienda o los anuncios de televisión.	+61.5%	+2.8%	+31.4%
Margen operativoLa puntuación de eficiencia del 'trabajo diario'. De cada dólar que gasta un cliente, esto muestra cuántos centavos mantiene la empresa después de fabricar el producto Y pagar todos los gastos generales corporativos (como salarios, marketing y mantener las luces encendidas).	+5.0%	+1216.4%	-105.7%
Margen netoEl porcentaje final que se lleva a casa. Cuando se eliminan todos los costos concebibles, impuestos y pagos de intereses, este es el número exacto de centavos que la empresa realmente se queda de cada dólar en ventas.	-0.4%	+87.8%	-623.0%
Flujo de caja libreEl santo grial del efectivo corporativo. Es el dinero físico gastable que queda después de que el negocio paga sus operaciones diarias Y compra las actualizaciones grandes y costosas (como nuevas fábricas o servidores) que necesita para sobrevivir. Este es el dinero 'libre' que pueden usar para pagar dividendos o recomprar acciones.	$69.8M	+17.4%	+91.7%
Margen FCFLa tasa definitiva de conversión de efectivo. Muestra qué tan buena es la empresa para convertir ventas regulares directamente en efectivo frío, duro y gastable. Un porcentaje alto significa que el negocio es una auténtica máquina de imprimir dinero.	+16.7%	+8.0%	+119.7%
Deuda/PatrimonioEl indicador de riesgo financiero. Compara cuánto del imperio de la empresa se construyó con dinero prestado (préstamos) frente al dinero propio de los propietarios (accionistas). Un número alto significa que están muy apalancados y juegan un juego más arriesgado; un número bajo significa que juegan a lo seguro.	1.1%	-96.4%	+2.3%
Ratio corrienteLa verificación de supervivencia de 12 meses. Simplemente compara el efectivo que tienen ahora mismo (más cosas que pueden convertirse rápidamente en efectivo) con las facturas inmediatas que absolutamente deben pagar este año. Una puntuación superior a 1 significa que tienen suficiente en la billetera para cubrir las próximas facturas sin entrar en pánico.	2.05x	-3.4%	+35.9%
Activos totalesEl tamaño absoluto del imperio de la empresa. Agrupa absolutamente todo lo valioso que poseen, desde el efectivo en la caja registradora y el inventario en el almacén, hasta las patentes de software en la bóveda y las fábricas en el suelo.	$1.6B	-1.2%	-6.7%

Real vs estimado

A Dec 31Q Sep 30

Métrica	Anual (real vs estimado)	Sorpresa anual	Trimestral (real vs estimado)	Sorpresa trimestral
EPS Surprise	-0.01 vs 0.46	-102.2%	-0.36 vs 0.09	-505.1%
Revenue Surprise	$418.8M vs $418.1M	+0.2%	$93.3M vs $92.8M	+0.6%

Transacciones de insiders de CERT

Compras (A)

Since Jun 1, 2026

Ventas (D)

Since Jun 1, 2026

Acciones mensuales compradas/vendidas con tendencia del precio de cierre (fuente diaria compartida)

Resumen de trading de insiders

Fecha	Ejecutivo	Cargo	Valor	Lado	Acciones	Precio
Sep 1, 2026	Mohammed Faiz	officer: Interim CFO	Restricted Stock Units	A	63,532	—
Jul 15, 2026	Mohammed Faiz	officer: Interim CFO	Common Stock	—	0	—
Jul 15, 2026	Mohammed Faiz	officer: Interim CFO	Restricted Stock Units	—	13,290	—
Jul 15, 2026	Mohammed Faiz	officer: Interim CFO	Performance Stock Units	—	8,544	—
Jun 1, 2026	Anhalt Rona	officer: Chief Human Resources Officer	Common Stock	A	7,147	—

Transcripción de la llamada de resultados de CERT

1 segmentos de transcripción

Q2 2026

Ponente desconocido

Operator: Good day, and thank you for standing by. Welcome to the Certara Second Quarter 2026 Earnings Conference Call. [Operator Instructions]. Please be advised that today's conference is being recorded. I would now like to hand the conference over to Jay Liu, Investor Relations at LifeSci. Please go ahead. Jay Liu: Good morning, everyone. Thank you all for participating in today's conference call. On the call from Certara, we have Jon Resnick, Chief Executive Officer; and Faiz Mohammed, Interim Chief Financial Officer. Earlier today, Certara released financial results for the quarter ended June 30, 2026. A copy of the press release is available on the company's website. Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements, and actual results may differ materially from those expressed or implied in the forward-looking statements. Please refer to Slide 2 in the accompanying presentation titled Second Quarter 2026 Financial Results for additional information, which you can find on the company's Investor Relations website. In their remarks or responses to questions, management may mention some non-GAAP financial measures. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures are available in the recent earnings press release available on the company's website. Please refer to the reconciliation tables in the accompanying materials for additional information. This conference call contains time-sensitive information and is accurate only as of today, August 4, 2026. Certara disclaims any obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise. And with that, I will turn the call over to Jon. Jon Resnick: Thank you for joining today's call. Before I get into our results, I want to highlight the appointment of our new Chief Commercial Officer, which we announced earlier this morning. This reflects our commitment to a new, more impactful go-to-market approach, which I'll cover in more detail shortly. The second quarter was about executing on our commitments. Overall, we are pleased with our progress. We are transforming Certara into a company we believe is capable of delivering sustainable double-digit growth. We still have work to do, but we are on the right path. We are executing against our plan. Our foundation is strengthening and the macro market conditions, biopharma spending, clinical trial starts and new regulatory guidance continue to be in our favor. I'll start with our top line financials, then move to our strategic and operational priorities, our client impact and finally, how we are leveraging AI. Top line results in the quarter were in line with expectations and guidance. Overall, revenue growth was modest at 1% with software revenue growing 4% and service revenue declining 3%. On software, …

Equipo directivo de CERT

14 directivos

Nombre	Cargo	Remuneración	Género	Año de nacimiento	Estado
Jon Resnick	Chief Executive Officer & Director	USD 1,404,299	Male	1973	Active
Adrian K. McKemey	President of Drug Development Solutions	USD 1,075,132	—	—	Active
John E. Gallagher	SVP, Principal Accounting Officer & Chief Financial Officer	USD 924,248	Male	1973	Active
Robert Aspbury	President of Certara Predictive Technologies	USD 826,125	—	1972	Active
Julien Perrier	President & Chief Commercial Officer	USD 690,082	Male	—	Active
Leif E. Pedersen	Senior Advisor	USD 690,082	Male	1965	Active
Faiz Mohammed	Interim CFO, Senior VP of Finance, Treasurer and Principal Financial & Accounting Officer	—	Male	1973	Active
Eric Jahn	Chief Information Officer	—	—	—	Active
Martin Snyder	President of Certara Data Sciences	—	Male	—	Active
Rona Anhalt	Chief Human Resources Officer	—	Female	1965	Active
Sheila Rocchio	Chief Marketing Officer	—	Female	—	Active
Christopher Bouton	Chief Technology Officer & Chief AI Officer	—	—	—	Active
Ron DiSantis	Senior Vice President of Corporate Development	—	Male	—	Active
Daniel Corcoran	Senior Vice President, General Counsel & Secretary	—	Male	1967	Active

Noticias recientes de CERT

Seeking Alpha4/8/2026Neutral

Certara, Inc. (CERT) Q2 2026 Earnings Call Transcript

MarketBeat4/8/2026Neutral

Certara Q2 Earnings Call Highlights

Certara NASDAQ: CERT reported second-quarter 2026 revenue of $93.3 million, up 1% year over year, as software growth offset a decline in services revenue. Management reaffirmed its full-year revenue outlook while outlining further changes to its commercial organization, cost structure and artificial intelligence strategy.

Zacks Investment Research4/8/2026Neutral

Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates

Certara, Inc. (CERT) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.07 per share a year ago.

GlobeNewsWire4/8/2026Neutral

Certara Reports Second Quarter 2026 Financial Results

Appoints Julien Perrier Chief Commercial Officer Completes previously authorized $100 million share repurchase program; Board authorizes additional $50 million under repurchase program Reaffirms 2026 revenue guidance RADNOR, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its second quarter 2026 financial results.

PRNewsWire23/7/2026Neutral

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT

NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Evolución del número de empleados de CERT

Actual

1,515

Cambio

+1.88%

Mínimo

1,054

Máximo

1,515

Presentaciones recientes

Fecha del informe	Empleados	Tipo de formulario	Fecha de presentación	Archivo SEC
31 dic 2025	1,515	10-K	26 feb 2026	Ver
31 dic 2024	1,487	10-K	26 feb 2025	Ver
31 dic 2023	1,338	10-K	29 feb 2024	Ver
31 dic 2022	1,150	10-K	1 mar 2023	Ver
31 dic 2021	1,054	10-K	1 mar 2022	Ver

Acciones relacionadasMedical - Healthcare Information Services

Ver todas las acciones de EE. UU. →

Sobre nosotrosPolítica de privacidadTérminos de servicioAviso legalDirectorio de accionesETFÍndicesCarteras 13FPrecios objetivoHerramientas gratuitasMapa tecnológicoÚnete a nuestro Slack

Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal

Certara, Inc.